Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653554 | 0.85 | CDC7 (0.49) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL2022675 | 0.85 | ALDH1A1 (0.49) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL17857202 | 0.84 | LOXL2 (0.46) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL30225376 | 0.84 | RECQL (0.50) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL30163441 | 0.84 | CYP19A1 (0.43) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL191073 | 0.84 | GABRP (0.61) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL16318640 | 0.84 | CYP4F2 (0.55) | CYP4Z1LMNASYKMAPT | |
| SCHEMBL2789335 | 0.84 | CYP19A1 (0.43) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL191331 | 0.84 | RECQL (0.50) | SMN1; SMN2NPC1PKMNFKB1RAB9A | |
| SCHEMBL12302554 | 0.83 | WNT3A (0.56) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129930-A1 | ALKYLPYRIDINIUM COUMARIN DYES AND USES IN SEQUENCING APPLICATIONS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20220195196-A1 | ALKYLPYRIDINIUM COUMARIN DYES AND USES IN SEQUENCING APPLICATIONS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-5807852-A | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5807853-A | Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5719148-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5714609-A | FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE | SCHERING CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0819128-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5700806-A | FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 1997-12-23 | — | — | US | disclosed |
| US-5696121-A | 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1996031111-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0723540-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010516-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | SMN1; SMN2 4623/4885NPC1 3747/4885PKM 804/4885 |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | SMN1; SMN2 4075/4885NPC1 3383/4885PKM 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.